Clinical Trials Logo
  1. Home
  2. Japanese Encephalitis
  3. NCT03204227

Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age — JECEVAX-2B  

Japanese Encephalitis Clinical Trial

Official title:
Evaluate the Safety of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by The Company for Vaccine and Biological Production No.1 in Vietnamese Children Aged 9-24 Months

Clinical Trial Summary

A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).

Clinical Trial Description

Mouse brain-derived Japanese Encephalitis (JE) vaccine was developed in Vietnam since 1989 with the support from WHO and BIKEN institute, Japan. It helped Viet Nam prevents Japanese Encephalitis outbreaks successfully during those years.

However, mouse brain-derived JE vaccine production requires companies to compliance various requirements from WHO. Especially, WHO has a plan to replace the mouse brain-derived JE vaccines with Cell culture-derived JE vaccines.

Vero cell-derived vaccine technology shows many advantages compares to Mouse brain-derived vaccine technology. VABIOTECH has been approved and sponsored by the Ministry of Science and Technology to produce Vero cell - derived JE vaccine. The vaccine demonstrated a good safety and immunogenicity profile in animal models. The vaccine has been proven safety in volunteer adults and in phase 2 which evaluated the safety and immunogenicity of 3 difference antigen concentrations.

In this study, a selected dose of the studied vaccine (JECEVAX) derived from phase 2 will be compared the safety with a licensed vaccine (JEVAX-VABIOTECH Vietnam) in Vietnamese children, aged 9-24 months to assess the safety and immunogenicity. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of investigate vaccines or control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose (up to date of 2nd dose) and from the second dose to 28-34 days after 2nd dose (up to date of 3rd visit). SAE (from start of first dose to 28-34 days after second dose - date of 3rd visit). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03204227
Study type Interventional
Source National Institute of Hygiene and Epidemiology, Vietnam
Contact
Status Completed
Phase Phase 2
Start date June 2, 2017
Completion date August 12, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT03282370 - Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam Phase 3
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Completed NCT00776230 - Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling Phase 3
Completed NCT00594958 - Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00595790 - Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00604708 - Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00596271 - Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 Phase 3
Not yet recruiting NCT01954810 - Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Phase 4
Completed NCT01246479 - Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Phase 3
Completed NCT00605085 - Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00596102 - Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00595270 - Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00314132 - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Phase 3
Active, not recruiting NCT01981967 - Post-licensure Safety Study of IMOJEV® in Thailand Phase 4
Completed NCT01466387 - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Phase 3
Completed NCT00314145 - A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX Phase 3
Completed NCT00981630 - Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Phase 2
Completed NCT01656200 - A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Phase 4
Completed NCT01567865 - Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Phase 4
Unknown status NCT01163123 - Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan N/A